Evidence map›Paper›PMID 29024573›Full record

ArticleCancer medicine2017

Targeting MTA1/HIF-1α signaling by pterostilbene in combination with histone deacetylase inhibitor attenuates prostate cancer progression.

Nasir A Butt, Avinash Kumar, Swati Dhar, Agnes M Rimando, Israh Akhtar, John C Hancock, Janice M Lage, Charles R Pound, Jack R Lewin, Christian R Gomez and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Nasir A ButtCancer Institute, University of Mississippi Medical Center, Jackson, Mississippi.
Avinash KumarCancer Institute, University of Mississippi Medical Center, Jackson, Mississippi.
Swati DharCancer Institute, University of Mississippi Medical Center, Jackson, Mississippi.
Agnes M RimandoUnited State Department of Agriculture, Agriculture Research Service, Natural Product Utilization Research Unit, University, Mississippi.
Israh AkhtarDepartment of Pathology, University of Mississippi Medical Center, Jackson, Mississippi.
John C HancockDepartment of Pathology, University of Mississippi Medical Center, Jackson, Mississippi.
Janice M LageDepartment of Pathology, University of Mississippi Medical Center, Jackson, Mississippi.
Charles R PoundDivision of Urology, Department of Surgery, University of Mississippi Medical Center, Jackson, Mississippi.
Jack R LewinDepartment of Pathology, University of Mississippi Medical Center, Jackson, Mississippi.
Christian R GomezCancer Institute, University of Mississippi Medical Center, Jackson, Mississippi.
Anait S LevensonCancer Institute, University of Mississippi Medical Center, Jackson, Mississippi.ORCID http://orcid.org/0000-0003-0646-2575

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The metastasis-associated protein 1(MTA1)/histone deacetylase (HDAC) unit is a cancer progression-related epigenetic regulator, which is overexpressed in hormone-refractory and metastatic prostate cancer (PCa). In our previous studies, we found a significantly increased MTA1 expression in a prostate-specific Pten-null mouse model. We also demonstrated that stilbenes, namely resveratrol and pterostilbene (Pter), affect MTA1/HDAC signaling, including deacetylation of tumor suppressors p53 and PTEN. In this study, we examined whether inhibition of MTA1/HDAC using combination of Pter and a clinically approved HDAC inhibitor, SAHA (suberoylanilide hydroxamic acid, vorinostat), which also downregulates MTA1, could block prostate tumor progression in vivo. We generated and utilized a luciferase reporter in a prostate-specific Pten-null mouse model (Pb-Cre

Indexed as

AnimalsAntineoplastic Combined Chemotherapy ProtocolsCell Line, TumorCell ProliferationCell SurvivalGene SilencingHistone DeacetylasesHydroxamic AcidsHypoxia-Inducible Factor 1, alpha SubunitInterleukin-1betaMaleMiceMice, KnockoutProstatic NeoplasmsPTEN PhosphohydrolaseRepressor ProteinsHif1a protein, mouseHistone DeacetylasesHydroxamic AcidsHypoxia-Inducible Factor 1, alpha SubunitInterleukin-1betaMta1 protein, mousePTEN PhosphohydrolasePten protein, mousepterostilbeneRepressor ProteinsStilbenesTrans-ActivatorsTranscription FactorsVascular Endothelial Growth Factor Cvascular endothelial growth factor C, mouseVorinostatCombination strategyMTA1prostate cancerPten knockout micepterostilbeneSAHA

Identifiers

PMID29024573
PMCPMC5673954

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.